Retreatment with pegylated interferon alpha-2a/2b and ribavirin in previous relapsers with chronic hepatitis C

Zhu Yan; Mao Qing; Zhang ZhangJiang; Sun Wei; Hu YaJun; Tan ChaoXia; Wang XiaoHong

Issue 1

Jan. 2011

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2011 > 27(1): 86-88

PDF( 2488 KB)

Retreatment with pegylated interferon alpha-2a/2b and ribavirin in previous relapsers with chronic hepatitis C

Published Date: 2011-01-20

Abstract

Abstract

Objective To assess the effectiveness and to investigate the influencing factors of pegylated interferon α-2a/2b (PEG-IFNα-2a/2b) and ribavirin retreatment in patients with chronic hepatitis C (CHC) after initial course of IFN or PEG-IFNα-2a/2b plus ribavirin rherapy.Methods A retrospective study was designed to analyze retreatment with IFN or PEG-IFNα-2a/2b plus ribavirin of 30 relapsed CHC patients.All of them received PEG-IFNα-2a at a dose of 180μg/week or PEG-IFNα-2b 1.5μg·kg-1·week-1 and ribavirin at a dose of 900mg/day for 24 or 48 weeks depending on the HCV genotype.The main parameter to evaluate the effectiveness was sustained virologic response (SVR) rate.The influences of HCV RNA load at the baseline, genotype and previous drug categories on response to IFN were analyzed.Results The SVR rate was 80% for all the patients.The SVR rate of the patients with low viral loads (HCV RNA≤1×105copies/ml) was markedly higher than that of the patients with high viral loads (HCV RNA>1×105copies/ml) (94.4% and 58.3%, P=0.026) .The HCV genotype and previous drug categories did not affect the likelihood of SVR although this may be the result of the relatively small number of patients.Conclusion Relapse after previous IFN or PEG-IFNα-2a/2b plus ribavirin therapy is associated with a strong probability of treatment success.Baseline serum HCV RNA load is a predictive parameter of SVR.
- hepatitis C,
- chronic,
- interferon alfa-2a

FullText(HTML)

References(11)

References

[1]Sherman M, Shafran S, Burak K, et al.Management of chronic hepatitis C:consensus guidelines[J].Can J Gastroenterol, 2007, 21 (Suppl C) :25C-34C.

[2]Hadziyannis SJ, Sette H Jr, Morgan TR, et al.Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose[J].Ann Intern Med, 2004, 140 (5) :346-355.

[3]Chinese society of infectious diseases and parasitology and chinese society of hepatology of Chinese medical association.The programme of prevention and cure for viral hepatitis[J].Chin J Hepatol, 2000, 8 (6) :324-329.

[4]熊瑜琳, 张长江, 王小红, 等.中国人HCV标本库的建立[J].免疫学杂志, 2008, 24 (5) :568-571.

[5]Sherman M, Yoshida EM, Deschenes M, et al.Peginterferon alfa-2a (40 KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy[J].Gut, 2006, 55 (11) :1631-1638.

[6]Yoshida EM, Sherman M, Bain VG, et al.Re-treatment with pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy[J].Can J Gastroenterol, 2009, 23 (3) :180-184.

[7]Poynard T, Colombo M, Bruix J, et al.Peginterferon alfa-2b and ribavirin:effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy[J].Gastroenterology, 2009, 136 (5) :1618-1628.

[8]Ge D, Fellay J, Thompson AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Nature, 2009, 461 (7262) :399-401.

[9]Suppiah V, Moldovan M, Ahlenstiel G, et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J].Nat Genet, 2009, 41 (10) :1100-1104.

[10]Tanaka Y, Nishida N, Sugiyama M, et al.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J].Nat Genet, 2009, 41 (10) :1105-1109.

[11]Shiratori Y, Kato N, Yoshida H, et al.How soon can a virological sustained response be determined after withdrawal of interferon therapy in chronic hepatitis C?Tokyo-Chiba Hepatitis Research Group[J].J Gastroenterol Hepatol, 1999, 14 (1) :79-84.

Relative Articles

[1]	Xu JinFeng, Zhang XiaoHui, Liu YaLi, Zhang Jing. Influencing factors for hemolytic anemia in patients with chronic hepatitis C treated by ribavirin combined with pegylated interferon-α[J]. Journal of Clinical Hepatology, 2019, 35(2): 319-322. doi: 10.3969/j.issn.1001-5256.2019.02.015
[2]	Yang CaiXia. Immune tolerance after drug withdrawal in a patient with chronic hepatitis B receiving PEG- IFNα- 2a treatment[J]. Journal of Clinical Hepatology, 2017, 33(1): 160-162. doi: 10.3969/j.issn.1001-5256.2017.01.035
[3]	Wu XiaoLi. Influence of combination mode of PEG-IFNα-2a and adefovir dipivoxil on outcome of patients with HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2017, 33(12): 2311-2315. doi: 10.3969/j.issn.1001-5256.2017.12.011
[4]	Zhang Yu, Cao Ying, Zhang RenWen, Zhang XiaXia, Lu HaiYing, Wu ChiHong, Huo Na, Yu Min, Liu Dan, Xu XiaoYuan. Natural resistance mutations to direct- acting antiviral agents in interferon / ribavirin treatment- experienced and treatment- nave patients with chronic hepatitis C in Beijing,China[J]. Journal of Clinical Hepatology, 2016, 32(4): 711-715. doi: 10.3969/j.issn.1001-5256.2016.04.020
[5]	Chen XiaoYun, Zheng YanHong, Jin Yi, Yu HaiBin, Ma LiNa, Chen XinYue. Correlation between routine blood test results and antiviral effect in patients with refractory chronic hepatitis C treated with pegylated interferon-α[J]. Journal of Clinical Hepatology, 2016, 32(7): 1319-1322. doi: 10.3969/j.issn.1001-5256.2016.07.021
[6]	Yang Long, Yang Yang, Jiang XueHua, Chen ZhiYong. Efficacy of peginterferon α- 2a in treatment of chronic hepatitis B resistant to multiple nucleos( t) ide analogues[J]. Journal of Clinical Hepatology, 2016, 32(4): 691-694. doi: 10.3969/j.issn.1001-5256.2016.04.016
[7]	Peng MeiJuan, Wang Wei, Yang XiaoFei, Hao ChunQiu, Bai XueFan, Jia ZhanSheng, Lian JianQi, Zhang Ye. Influence of pegylated interferonα- 2a versus telbivudine on renal function in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(4): 682-686. doi: 10.3969/j.issn.1001-5256.2016.04.014
[8]	Sun JianMin. Efficacy of low-dose interferon α-1b combined with ribavirin and thymosin α1 versus standard treatment for chronic hepatitis C: a comparative study [J]. Journal of Clinical Hepatology, 2015, 31(1): 107-109. doi: 10.3969/j.issn.1001-5256.2015.01.023
[9]	Liu YunHua, Li Zhen, Liu Li, Peng Dan, Li WeiKun, Chang LiXian, Jia Ting, Yang YongRui, Li HuiMin, Wang LiQian. Clinical study of pegylated interferon α-2a in treatment of children with HBe Ag-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(2): 193-197. doi: 10.3969/j.issn.1001-5256.2015.02.012
[10]	Liu ZhiHua, He HaiTang, Hu Jing, Fu QunXiang, Luo KangXian. Efficacy of pegylated interferon α-2a in HBe Ag-negative chronic hepatitis B patients and its influencing factors[J]. Journal of Clinical Hepatology, 2015, 31(5): 697-701. doi: 10.3969/j.issn.1001-5256.2015.05.016
[11]	Lin Wei, Si JianLin, Zhang Jian, Maimaitijiang·Wubuliaishan, Hu ZhiMing, Li DongZeng, Geng Nan. Pegylated interferon alpha-2a combined with ribavirin for chronic hepatitis C: a clinical analysis of 160 patients of Uygur nationality or Han nationality[J]. Journal of Clinical Hepatology, 2015, 31(11): 1831-1836. doi: 10.3969/j.issn.1001-5256.2015.11.015
[12]	Cai ShaoPing, Zhang WenJin, He WeiPing, Fan ZhenPing, Ji YingJie. Efficacy and safety of interferon plus ribavirin in elderly patients with chronic hepatitis C: report of 4 cases[J]. Journal of Clinical Hepatology, 2014, 30(1): 69-71. doi: 10.3969/j.issn.1001-5256.2014.01.019
[13]	Lu JianGuo. Effect of pegylated interferon α-2a combined with thymosin α1 on quality of life in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(12): 922-925. doi: 10.3969/j.issn.1001-5256.2013.12.012
[14]	Zhao XiaoLing, Zhang YongGang. Clinical efficacy of ribavirin combined with different doses of interferon α- 2b in patients with chronic hepatitis C genotypes 2 and 3[J]. Journal of Clinical Hepatology, 2013, 29(10): 780-783. doi: 10.3969/j.issn.1001-5256.2013.10.014
[15]	Zhang SuMei, Xie YuMei, Zhang Ying, Guo YongHong, Wei Xin, Jiang Na, Zhou Yun, Jia ZhanSheng. Potential of G-CSF supplementation to counter the neutrophil effects of standard PEG-IFNα plus ribavirin combination therapy for treating HCV-related cirrhosis [J]. Journal of Clinical Hepatology, 2013, 29(5): 348-351.
[16]	Hao KunYan, He ZhangLun, Yu LeCheng, Sheng YunFeng, Wang MaoRong. Rhabdomyolysis during the antiviral therapy against chronic hepatitis C with the combination of interferon and ribavirin:a case report[J]. Journal of Clinical Hepatology, 2011, 27(6): 654-655.
[17]	Zhu HaiJuan, Li YongHong, Guo LiPing. One case report of hysteria in a HCV patient being treated with PEG-IFN α-2a[J]. Journal of Clinical Hepatology, 2011, 27(6): 656-657.
[18]	Wei Xin, Xie YuMei, Chen Lin, Pan Lei, Hao ChunQiu, Wang JiuPing, Bai XueFan, Jia ZhanSheng. Antiviral therapy with pegylated interferon alpha-2a plus ribavirin in patients with HCV related cirrhosis and to establish the grading for standard therapy[J]. Journal of Clinical Hepatology, 2011, 27(1): 89-92.
[19]	Zheng YingYing, Fan XiaoHong, Wang LiFen, Tian Di, Huo Na, Lu HaiYing, Wu ChiHong, Xu XiaoYuan, Wei Lai. Efficacy and side effects of PEG-IFNα-2a plus ribavirin on elderly patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(8): 821-823.
[20]	Jiang XueQiang, Zou XiaoJing, Tian DeYing. Virological response of chronic hepatitis C treated with peg-interferon α-2a and Ribavirin[J]. Journal of Clinical Hepatology, 2011, 27(4): 417-419.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2632) PDF downloads(839)

Retreatment with pegylated interferon alpha-2a/2b and ribavirin in previous relapsers with chronic hepatitis C

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Retreatment with pegylated interferon alpha-2a/2b and ribavirin in previous relapsers with chronic hepatitis C

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content